Dimensional Fund Advisors LP Purchases 97,510 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Dimensional Fund Advisors LP boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 968.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 107,580 shares of the company's stock after purchasing an additional 97,510 shares during the period. Dimensional Fund Advisors LP owned about 0.17% of Viridian Therapeutics worth $1,400,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Viridian Therapeutics by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company's stock worth $56,632,000 after buying an additional 233,331 shares during the period. Candriam S.C.A. boosted its stake in Viridian Therapeutics by 167.8% during the second quarter. Candriam S.C.A. now owns 749,804 shares of the company's stock worth $9,754,000 after acquiring an additional 469,804 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Viridian Therapeutics by 37.4% during the second quarter. Bank of New York Mellon Corp now owns 208,676 shares of the company's stock worth $2,715,000 after acquiring an additional 56,814 shares in the last quarter. Kopp LeRoy C bought a new stake in Viridian Therapeutics during the first quarter worth about $3,601,000. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in Viridian Therapeutics by 62.9% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 178,855 shares of the company's stock worth $2,327,000 after acquiring an additional 69,035 shares in the last quarter.

Insider Buying and Selling at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc bought 1,600,000 shares of the company's stock in a transaction on Friday, September 13th. The shares were purchased at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the transaction, the director now directly owns 3,445,813 shares of the company's stock, valued at approximately $64,608,993.75. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, COO Thomas W. Beetham acquired 5,000 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $23.41 per share, with a total value of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at approximately $140,460. The trade was a 500.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Fairmount Funds Management Llc bought 1,600,000 shares of the stock in a transaction on Friday, September 13th. The stock was acquired at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the acquisition, the director now directly owns 3,445,813 shares in the company, valued at approximately $64,608,993.75. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 1,626,400 shares of company stock valued at $30,616,312 in the last three months. Corporate insiders own 0.65% of the company's stock.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN traded up $1.63 during midday trading on Friday, hitting $23.63. 1,218,766 shares of the stock were exchanged, compared to its average volume of 1,356,414. The company has a 50 day moving average price of $18.43 and a 200-day moving average price of $15.60. Viridian Therapeutics, Inc. has a twelve month low of $10.93 and a twelve month high of $24.75. The stock has a market cap of $1.51 billion, a P/E ratio of -5.56 and a beta of 1.08. The company has a current ratio of 15.82, a quick ratio of 15.82 and a debt-to-equity ratio of 0.05.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.15). Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 83.18%. The business had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.09 million. On average, research analysts forecast that Viridian Therapeutics, Inc. will post -3.94 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VRDN has been the subject of several research reports. Needham & Company LLC boosted their price objective on shares of Viridian Therapeutics from $30.00 to $38.00 and gave the company a "buy" rating in a report on Wednesday, September 11th. Oppenheimer reissued an "outperform" rating and issued a $28.00 price objective (down from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. HC Wainwright restated a "buy" rating and set a $27.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, September 10th. BTIG Research increased their price objective on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, September 26th. Finally, The Goldman Sachs Group increased their target price on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a "buy" rating in a research note on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.80.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.